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Abstract
Immunotherapy of feline immunodeficiency virus (FIV)-infected cats with monocyte-derived
dendritic cells (MDCs) loaded with aldrithiol-2 (AT2)-inactivated homologous FIV was performed.
Although FIV-specific lymphoproliferative responses were markedly increased, viral loads and
CD4+ T cell depletion were unaffected, thus indicating that boosting antiviral cell-mediated
immunity may not suffice to modify infection course appreciably.
Findings
Cell-mediated immune responses involving polyfunc-
tional CD8+ and CD4+ T cells are considered pivotal in the
control of human immunodeficiency virus (HIV)-1 infec-
tion [1]. Dendritic cells (DCs) are the only antigen-pre-
senting cells that are able to present exogenous antigens to
both helper and cytotoxic T cells; in order to do so, DCs
must undergo maturation after antigen uptake, a process
that can be started by cytokines and microbial products
like lipopolysaccharide (LPS) [2,3]. Early clinical trials
exploring autologous DCs that were loaded with antigens
ex vivo to induce T-cell responses have provided proof of
principle that DCs might be exploited in the therapy and/
or prevention of various types of disease [4]. Recently,
DCs have been also tested in the immunotherapy of HIV-
1 and simian immunodeficiency virus infections [5,6]; in
particular, Lu and colleagues have reported that stimulat-
ing the immune system with autologous monocyte-
derived DCs pulsed with AT2-inactivated whole HIV-1 is
beneficial in the treatment of chronic HIV-1 infection [5].
FIV is a non-primate lentivirus that has long been studied
as a model for HIV [7]. The infection it establishes in cats
closely resembles human AIDS, causing progressive
immune deficiency and allowing it to be considered one
of the best models to test different strategies against HIV-
1. We have recently tested vaccination of cats with autolo-
gous MDCs loaded with AT2-inactivated FIV and matured
with LPS (FIV-MDCs): such an approach elicited very high
proliferative responses against FIV and detectable anti-
body responses [8]. However, such vaccination did not
result in reduced infection of cats upon viral challenge.
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Because memory T cells have different requirements and
may behave differently from naïve T cells upon activation
[9], the present study was carried out to assess whether a
similar approach might boost memory immune
responses against FIV and lead to changes in immunolog-
ical and virological parameters in chronically infected
cats. The local isolate FIV-M2 was selected for the study,
because it has been passed a limited number of times in
tissue culture and preserves pathogenetic and neutraliza-
tion features typical of wild-type lentiviruses [10]. FIV-M2
used to load MDCs was produced in interleukin (IL)-2
dependent MBM cells [10] grown in 3% cat plasma and
inactivated by incubation with AT2 at a 300 μM final con-
centration at 4°C for 2 h, as described [8]. The virus thus
treated (AT2-FIV) was then concentrated and purified on
sucrose gradient for 3 h at 15,000 × g. A single stock con-
taining 800 μg/ml protein was used throughout the study.
FIV-MDCs used for immunotherapy were prepared from
heparinized jugular venous blood obtained under light
anesthesia, 7 days before each inoculum, as described
[11]. Briefly, peripheral blood mononuclear cells
(PBMCs) were washed in apyrogenic saline and resus-
pended in RPMI 1640 supplemented with 2 mM L-
glutamine, 1% non-essential amino acids, and 50 μg/ml
gentamycin. Nine × 106 cells/well were distributed in 6-
well plates, and then 3% autologous plasma was added.
After 24 h, non-adhering cells were washed away, and 1
ml of medium containing 3% autologous plasma, recom-
binant feline IL-4, 10 ng/ml, and recombinant feline gran-
ulocyte-macrophage colony stimulating factor (R&D
Systems, Minneapolis, MN), 50 ng/ml, were added. Every
other day, fresh cytokines were added and, at day 5 of cul-
ture, MDCs were incubated with 80 μg/ml AT2-FIV at
37°C in 5% CO2 for 2 h. This antigen dose was 4 times the
one used to load MDCs in our previous vaccine experi-
ment mentioned above [8], in an attempt to maximize
efficacy. Next, immediately after loading with the FIV anti-
gen, MDCs were induced to mature by exposing them to
10 ng/ml of LPS from E. coli 0127:B8 (Sigma, St Louis,
MO) for 48 h. FIV-MDCs were then checked for MHC
class II and B7.1 expression and for the ability to activate
mixed lymphocyte reactions in vitro, as previously
reported [8]: they exhibited high expression of MHC class
II and B7.1 compared to immature MDCs in FACS analy-
sis, and a highly upregulated ability to turn on reactivity
by allogeneic PBMCs (data not shown).
For immunotherapy, MDCs were generated, loaded and,
2 days after exposure to antigen and LPS, reinjected into
cats 3 times at 1-month intervals. In order to generate an
in situ environment improving DC maturation [12,13],
20 min before FIV-MDCs were injected, two skin sites
located on each thigh, close to the popliteal lymph nodes,
were shaved and pretreated with the Toll-like receptor-7
agonist imiquimod (Aldara®  cream, Laboratoires 3 M
Santé, Pontoise, France), that is also active for cats [14].
All FIV-MDCs obtained (Table 1) were resuspended in a
final volume of 1 ml of saline, and 0.5 ml were injected
subcutaneously at each site. Eleven specific-pathogen-free
female cats, bought from IFFA Credo (L'Arbresle, France)
and kept in our climate-controlled animal facility under
conditions required by the European Community Law,
were enrolled for this study. They had been infected intra-
venously with FIV-M2 [10] between 1 and 7 years before
(Table 1) and, for at least 16 weeks before treatment, had
Table 1: Numbers of FIV-DCs inoculated per immunization into each experimental cat.
Cat ID Years of infection FIV-binding antibody titera FIV-DCs reinoculated (× 106)
Inoculum
1st 2nd 3rd Total
DB 7 3200 2 2 2 6
DC 7 3200 - 0.5 1.5 2
EM 3 800 3 3 1 7
EQ 3 3200 3 2 3 8
S6 7 6400 0.5 2 0.5 3
S8 7 3200 1.5 1 1 3.5
S9 7 6400 1 - 0.5 1.5
S14 7 800 1.5 0.5 0.5 2.5
S15 7 800 0.5 2 1 3.5
GY15 1 400 1.5 2.5 3 7
HB17 1 400 4.5 2 2 8.5
a Titers are expressed as reciprocals of the highest serum dilutions that gave optical density readings at least threefold higher than the average 
values obtained with 10 control FIV-negative sera plus 3 times the standard deviation. Titers remained constant throughout the observation period.
b FIV-MDCs were generated from each individual cat as described in the text. On the days of treatment, they were harvested, counted and 
reinjected into the corresponding donor cats. Numbers represent live cells, as evaluated by trypan blue exclusion.Retrovirology 2008, 5:33 http://www.retrovirology.com/content/5/1/33
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exhibited essentially stable viral burdens in peripheral
blood and, as expected, generally low CD4+ T cell percent-
ages (Figure 1). FIV-specific PBMC proliferative activity
was determined by incubating 1.5 × 105 PBMCs in 96-well
plates in 200 μl medium supplemented with 10% human
serum with either 1 μg/well of purified sonicated FIV-M2
or no stimulus for 4 days, and counting after addition of
3H-thymidine (GE Healthcare, Milan, Italy) for 18 h.
Results are reported as stimulation index (S.I.), that is the
ratio of radioactivity incorporated by test PBMCs in the
presence or absence of antigen, which was considered
positive when >2 [10]. As shown by Figure 2a, prior to
treatment, most animals tested negative in this assay;
exceptions were cat GY, that had an S.I. of 7 at week -5,
and cat DC, that had an S.I. of 4 at week -16. Already 2
weeks after the first FIV-MDC inoculum, 5 cats had mark-
edly enhanced lymphoproliferative responses to FIV,
most of which peaked at 5 weeks, when 10 of the 11 cats
responded to therapy. Previous experiments in which cats
immunized with whole uninfected MBM cells (where the
virus used throughout the present study was produced)
failed to generate immune responses that could be
detected with the same assay used here, indicated that
reactivity to cell components incorporated in the FIV viri-
ons did not contribute significantly to proliferation [10].
However, to confirm that proliferation was truly FIV spe-
cific, we also determined reactivity of PBMCs to the viral
Gag. To this aim, a library of 58 15-mer overlapping pep-
tides covering the entire FIV-M2 Gag p24 region, staggered
by 4 amino acids, was resuspended at 1 mg/ml of each
peptide in 100% DMSO and used at 5 μg/ml in the same
assay. The results (Figure 2b) confirmed that proliferation
was indeed FIV specific. Again, maximum reactivity was
seen at week 5 post treatment, was still present in a good
proportion of cats at week 9, and in a few cats at week 15.
In contrast to cell mediated immunity, total binding anti-
body responses, determined by enzyme linked immuno-
sorbent assays against purified FIV-M2 [10], turned out to
be unaffected by therapy, in that plasma samples from
experimental cats showed the same titers before (Table 1)
and after treatment (not shown).
To determine the effect of immunotherapy on FIV infec-
tion, the viral burden in the peripheral blood of experi-
mental cats was measured at the time intervals shown in
Figure 1 up to 15 weeks after the initiation of treatment.
Plasma viremia was determined on RNA extracted from
plasma samples by reverse transcription TaqMan
polymerase chain reaction (TM-PCR). Proviral load in
PBMCs was determined on PBMC DNA by TM-PCR. Sen-
sitivities of the assays were 200 copies/ml of plasma and
100 copies/μg of genomic DNA, respectively [15]. As can
be seen in Fig 1, cat identified as S15 exhibited a dramatic
decrease in plasma viremia, but all the others remained at
the same levels as before therapy. On the other hand, pro-
viral DNA and CD4+ T cell percentages invariably under-
went no appreciable changes (Fig 1b and 1c).
The goal of vaccines in the therapy of viral diseases is the
induction of protective immune responses able to control
ongoing viral infection. Immunotherapy with AT2-FIV
loaded MDCs did elicit a sharp and marked increase in
FIV-specific PBMC proliferation. Although such an assay
may be a crude indicator of the actual state of T cells
involved in protection, we considered it as good as any
other, especially in the light of many lentiviral vaccination
experiments, dramatically confirmed by the recent failure
of the STEP vaccine candidate to protect against HIV infec-
tion [16]. Indeed, although immunogenicity of the latter
vaccine was demonstrated, mostly by ELISPOT, no protec-
tion was conferred to the vaccinees. In the present study,
one cat (S15) out of the 11 enrolled exhibited reduced
plasma viremia levels after FIV-MDC treatment, in parallel
with relatively high lymphoproliferative response
throughout the observation period. The significance of
this finding, however, is questionable since the levels of
viral DNA in the PBMCs and of circulating CD4+ T cells
remained unchanged. For all other cats, immunotherapy
showed no beneficial effects, at least as detectable by the
parameters monitored. This is in contrast with the afore
mentioned studies in primates performed by Lu et al.,
since these workers reported significant viral load
decreases in a high proportion of the subjects treated
beginning soon after initiation of therapy [5,6].
The fact that total anti-FIV antibodies remained constant
in titers throughout the observation period in our study
came to no surprise, firstly because we had observed rela-
tively low antibody responses in cats vaccinated with FIV-
MDCs [8], secondly because it has been observed also in
the immunotherapy of HIV patients by Lu and colleagues
[6]. This issue, however, might be key to explaining why
immunotherapy did not lead to a decrease in virus titers,
since recent evidence has shown that potent immune acti-
vation of the cellular arm is not sufficient to reduce virus
persistence in the absence of virus-specific neutralizing
antibodies, but rather it might favor the formation of
"sanctuaries" where viruses might persist undisturbed
[17]. Alternatively, since the study cats had been infected
for at least 1 year when they were treated, the virus they
harbored might have diverged substantially in the T
epitopes important for infection control from the virus
used for preparing the FIV-MDCs, which was the same
used for cat infection [18]. Another issue might be the low
numbers of antigen-loaded MDCs that were delivered to
the cats: although we did make an effort to obtain as many
MDCs at each inoculation time as possible, their numbers
were always much lower than the ones reported in studies
of this kind with primates [5,6]. However, as we previ-
ously noticed [8] and in agreement with other studiesRetrovirology 2008, 5:33 http://www.retrovirology.com/content/5/1/33
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Plasma viremia (a), proviral load in the PBMCs (b), and circulating CD4+ T lymphocyte percentages (c) of the study cats at the  times indicated relative to the first FIV-MDC inoculum Figure 1
Plasma viremia (a), proviral load in the PBMCs (b), and circulating CD4+ T lymphocyte percentages (c) of the 
study cats at the times indicated relative to the first FIV-MDC inoculum. CD4+ T cells were monitored by flow 
cytometry in peripheral blood by direct staining with anti-feline CD4-PE (clone vpg34, AbD Serotec, Raleigh, NC) for 30 min as 
previously described (8). Symbols represent individual animals. Arrows indicate the times of FIV-MDC inoculation.Retrovirology 2008, 5:33 http://www.retrovirology.com/content/5/1/33
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Virus-specific lymphoproliferative activity in the study cats Figure 2
Virus-specific lymphoproliferative activity in the study cats. At the times indicated relative to the first FIV-MDC inoc-
ulum, PBMCs were exposed to intact FIV-M2 virions (a) or to pooled FIV-M2 Gag oligopeptides (b) and then examined for 3H-
thymidine incorporation. Columns represent the stimulation index (S.I.) of individual animals, which was considered positive 
when above threshold dotted line (S.I. > 2). All cats responded to the nonspecific stimulus Concavalin A with counts per 
minute ranging from 10,000 to 38,000 counts per minute, while background proliferation in medium alone ranged between 100 
and 1,100. At each sampling point, the animals are represented in the same order as shown in Figure 1.Publish with BioMed Central    and   every 
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[6,19], there was little or no correlation between the total
amount of MDCs injected and the size of FIV-specific
PBMC proliferation these elicited.
To sum up, immunotherapy of FIV infected cats does not
seem to be an encouraging approach as currently per-
formed. Should the data in the SIV/HIV systems by Lu et
al [5,6] be confirmed independently, the question why
FIV-loaded MDCs do not elicit beneficial effects in
infected cats remains open. Differences between the
present study and the ones mentioned above include the
numbers of MDCs injected and the way maturation of
MDCs was achieved, with LPS in the present study and
with cytokines in the ones by Lu et al. Possible future
improvements might include the development of effective
strategies for in vivo targeting of antigen to DCs [20], but
this will require targeting molecules that still need to be
characterized in the cat model.
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